Shearman & Sterling represented a syndicate of 18 underwriters represented by Morgan Stanley, Barclays, Citigroup, Goldman, Sachs & Co. and J.P. Morgan in connection with Amgen’s benchmark offering of $4.5 billion of investment grade notes, consisting of $850 million of 1.250% senior notes due 2017, $1.4 billion of 2.200% senior notes due 2019, $1.4 billion of 3.625% senior notes due 2024, $600 million of senior floating rate notes due 2017, and $250 million of senior floating rate notes due 2019.
Amgen is a global biotechnology company that discovers, develops, manufactures and delivers innovative human therapeutics based on advances in cellular and molecular biology.
The following Shearman & Sterling team advised the underwriters in the transaction: partners John Wilson (San Francisco-Capital Markets), Alan Seem (Palo Alto-Capital Markets), Larry Crouch (Palo Alto-Tax), and Richard Hsu (Palo Alto-Intellectual Property Transactions); counsel Eileen O’Pray (Palo Alto-Tax), Daniel Stellenberg (Palo Alto-Executive Compensation & Employee Benefits), and Emily Griffen (San Francisco-Litigation); and associates Nathan Mee, Scott Lucas (both San Francisco-Capital Markets), Jennifer Morton, Jenny Ding (both New York-Financial Institutions Advisory & Financial Regulatory), Zheng Bao (Palo Alto-Intellectual Property Transactions) and Alice Townes (Palo Alto-Tax).
